1. Sustained lymphocyte decreases after treatment for early breast cancer
- Author
-
Julia Dixon-Douglas, Balaji Virassamy, Kylie Clarke, Michael Hun, Stephen J. Luen, Peter Savas, Courtney T. van Geelen, Steven David, Prudence A. Francis, Roberto Salgado, Stefan Michiels, and Sherene Loi
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal study of full blood counts (FBC) of 200 patients receiving (neo)adjuvant chemotherapy for early breast cancer at a single institution. FBC results at four time points from pre-treatment to 12 months post-chemotherapy were analysed. Flow cytometry was performed for patients with matched pre- and post-chemotherapy peripheral blood mononuclear cell samples. A significant decrease in absolute lymphocyte count at 12 months post-chemotherapy was observed (p
- Published
- 2024
- Full Text
- View/download PDF